Literature DB >> 6138616

24 hour intragastric acidity and single night-time dose of three H-2-blockers.

H G Dammann, P Müller, B Simon.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6138616     DOI： 10.1016/s0140-6736(83)91057-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in gastric ulcer healing.

Authors:  W Rösch
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.

Authors:  N Inotsume; M Nishimura; S Fujiyama; K Sagara; T Sato; Y Imai; H Matsui; M Nakano
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of bedtime ranitidine on overnight gastric acid output and intragastric pH: dose/response study and comparison with cimetidine.

Authors:  J B Chambers; D Pryce; J M Bland; T C Northfield
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

5.  Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

Authors:  D B Jones; C W Howden; D W Burget; G D Kerr; R H Hunt
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

6.  Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers.

Authors:  C Staiger; B Korodnay; J X Devries; E Weber; P Müller; B Simon; H G Dammann
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

7.  Randomized, double-blind comparison of famotidine with ranitidine in treatment of acute, benign gastric ulcer disease. Community-based study coupled with a patient registry.

Authors:  S R Brazer; M P Tyor; F S Pancotto; R S Brice; J T Garbutt; N M Wildermann; F E Harrell; D B Pryor; C L Liss; J K Root
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

Review 8.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 9.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

10.  Pharmacokinetics of famotidine in patients with cirrhosis and ascites.

Authors:  G Vinçon; C Baldit; P Couzigou; F Demotes-Mainard; L Elouaer-Blanc; B Bannwarth; B Begaud
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.